hemophilia
Hemophilia is divided into two types: A and B. Hemophilia A is a bleeding disease caused by the deficiency of coagulation factor VIII, accounting for about 85% of congenital bleeding diseases. According to the report of the joint meeting of the World Health Organization (WHO) and the World Federation of Hemophilia (WHF) in 1990, the incidence of hemophilia A is about 15-20/100,000 people. According to statistics from European and American countries, it is about 5-10/100,000 people. The incidence of hemophilia A in China is about 3-4/100,000 people. Hemophilia B, also known as factor IX deficiency or Christmas disease, has an incidence of about 1.0-1.5/105, accounting for 15%-20% of hemophilia. The gene of factor IX is 34kb long, located on the long arm of chromosome X, with 8 exons and 7 introns. Factor IX is a plasma protein dependent on vitamin K, with a relative molecular weight of 56,000, and is synthesized in the liver. The treatment of hemophilia A and B is similar, using replacement therapy, and plasma, prothrombin complex concentrate (PCC), factor IX concentrate and recombinant factor IX products can be used.
-
Site of disease:
Spinal cord blood vessels -
Infectious :
Not contagious -
Frequent population:
Often develops in childhood -
Related symptoms:
Skin bleeding spots Intra-articular bleeding Muscle bleeding Wounds that do not heal after tooth extraction Joint swelling -
Concurrent disease:
Related Drugs
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Sinopharm Shanghai Plasma-derived Biotherapies Co., Ltd.
Human coagulation factor VIII
Indication: This product has a corrective effect on coagulation dysfunction caused by lack of human coagulation factor VIII. It is mainly used to prevent and treat bleeding symptoms caused by hemophilia A and acquired coagulation factor VIII deficiency and to treat surgical bleeding in such patients.
Manufacturer:
Shanghai RAAS Blood Products Co., Ltd.
Human coagulation factor VIII
Indication: This product has a corrective effect on coagulation dysfunction caused by lack of human coagulation factor VIII. It is mainly used to prevent and treat bleeding symptoms caused by hemophilia A and acquired coagulation factor VIII deficiency and to treat surgical bleeding in such patients.
Manufacturer:
Hualan Biological Engineering,Inc.
Human coagulation factor VIII
Indication: This product has a corrective effect on coagulation dysfunction caused by lack of human coagulation factor VIII. It is mainly used to prevent and treat bleeding symptoms caused by hemophilia A and acquired coagulation factor VIII deficiency and to treat surgical bleeding in such patients.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Tranexamic acid tablets
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for: ① traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophiliacs with factor VIII or factor IX deficiency; ⑥ central artery
Manufacturer:
Zhengzhou Fusheng Pharmaceutical Co., Ltd.
Danazol Soft Capsules
Indication: It is mainly used to treat endometriosis. It is also used to treat fibromastitis, gynecomastia, breast pain, dysmenorrhea, abdominal pain, etc. It can make the lumps disappear, soften or shrink, and make the pain disappear or alleviate. It is also used to treat precocious puberty, idiopathic thrombocytopenic purpura, hemophilia and Christmas disease, hereditary angioedema, systemic lupus erythematosus, etc.
CYKLOKAPRON- tranexamic acid_injection, solution
Indication: CYKLOKAPRON registered CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
Manufacturer:
Pfizer Laboratories Div Pfizer Inc
Related Ingredients
-
N-T-BOC-ILE-GLU-GLY-ARG 7-AMIDO-4-METHYL-COUMARIN HYDROCHLORIDE list
102601-26-3